Skip to main content

Bioinformatics Training Course course KDMC11, July 12th - 15th, 2011, Portugal

There is an interesting course being run in Oeiras, Portugal in July.

About one hundred million different chemical compounds have already been synthesized. The number of theoretically possible organic molecules exceeds the number of atoms in the universe. This raises a number of questions, including:
  • Where can one find information about chemical structures and their properties?
  • How can one efficiently retrieve such information?
  • Which molecules, if synthesized, could potentially assist the fight against certain types of cancer?
  • Why is it that some pharmacological targets are considered more promising for the prevention or treatment of Alzheimer?s disease than others?
  • Are there ways to better predict ADME(T) properties of synthesized molecules?
  • Why does such a significant proportion of launched drugs originate from structures found in natural products?
  • Why can multi-target pharmacological agents be superior to single-targeted ones?
  • Can new medical applications be found for old drugs?
  • Why is the alliance of chemo- and bioinformatics beneficial to the life sciences, biotech and pharma industries?
  • What are the major challenges facing chemoinformatics now?
During this course participants will learn how to efficiently find answers to these and many other related questions. Attendees will be instructed in the use of the relevant databases and associated software to:
  • Represent compounds and (bio)chemical reactions using chemical information in a computer.
  • Search for information about chemical structures and their properties in public and commercially available databases.
  • Perform similarity searches with an understanding of the advantages and disadvantages of the various methods.
  • Prepare data sets for further (Q)SAR/(Q)SPR analysis, estimating the quality and completeness of the data.
  • Create and validate (Q)SAR/(Q)SPR models for finding and optimization of lead compounds.
  • Use the above techniques for virtual screening and design of chemical compounds with the required properties.
Target audience
Researchers working in life sciences, professionals in the pharmaceutical and biotech industries: organic, medicinal, pharmaceutical chemists, biochemists, molecular biologists, pharmacologists, toxicologists, and others.

Information on all GTPB courses can be found at


Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site: Please see ChEMBL_34 release notes for full details of all changes in this release: New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the